GLP1R and Parkinson disease: Liraglutide, a new GLP-1 mimetic with a longer biological half-life compared to exenatide, has been accepted by the FDA to treat patients with T2DM and obesity; however, it is currently undergoing a phase II trial to assess its efficacy and safety profiles as a potential drug for PD treatment (NCT02953665).